EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Left Atrial Appendage Closure versus Oral Anticoagulants in Patients with Atrial Fibrillation: Systematic Review

Heng Liu, Zhangbin Li, Xiaoqing Chen, Junjie Zhou

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261459709 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 09.06.2026. Verfasst von Heng Liu und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral anticoagulants (OACs) remain the standard strategy for stroke prevention in atrial fibrillation (AF) but are limited by bleeding risk, intolerance, and long-term adherence challenges. Left atrial appendage closure (LAAC) has emerged as a catheter-based alternative for thromboembolic prevention in non-valvular AF. This systematic review evaluated the comparative efficacy and safety of LAAC versus OAC therapy in patients with AF.

Methods

PubMed and Embase were systematically searched for randomized controlled trials (RCTs) comparing percutaneous LAAC with OACs, including direct oral anticoagulants (DOACs) and warfarin, in patients with AF.

Results

Four pivotal randomized trials (PROTECT AF, PREVAIL, PRAGUE-17, and OPTION) were included. Compared with DOAC therapy, LAAC demonstrated non-inferiority for the composite endpoint of all-cause death, stroke, or systemic embolism in OPTION and for the primary composite outcome in PRAGUE-17. LAAC was associated with significantly lower non-procedural bleeding compared with DOACs in OPTION and PRAGUE-17. Compared with warfarin, LAAC achieved non-inferiority for ischemic stroke or systemic embolism beyond 7 days after randomization in PREVAIL and reduced long-term cardiovascular mortality in PROTECT AF. Procedure-related complications declined with increasing operator experience.

Conclusion

LAAC provides non-inferior thromboembolic protection compared with OAC therapy while reducing long-term bleeding events in selected patients with AF. LAAC represents an important alternative for patients at elevated bleeding risk or with contraindications to long-term anticoagulation.

Zitieren

APA

Liu, H., Li, Z., Chen, X., & Zhou, J. (2026). Left Atrial Appendage Closure versus Oral Anticoagulants in Patients with Atrial Fibrillation: Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261459709

Vancouver

Liu H, Li Z, Chen X, Zhou J. Left Atrial Appendage Closure versus Oral Anticoagulants in Patients with Atrial Fibrillation: Systematic Review. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261459709

BibTeX
@article{Liu2026,
  author = {Liu, Heng and Li, Zhangbin and Chen, Xiaoqing and Zhou, Junjie},
  title = {Left Atrial Appendage Closure versus Oral Anticoagulants in Patients with Atrial Fibrillation: Systematic Review},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261459709}
}
Kostenlos starten →